{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:43:10Z","timestamp":1790012590977,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Simultaneously targeting key pathogenic drivers and remodeling of the tumor microenvironment represents a critical therapeutic strategy for relapsed or refractory (r\/r) multiple myeloma (MM) and lymphoma. Purinostat mesylate (PM), a highly selective HDAC I\/II binhibitor, exhibits excellent antitumor activity in MM and lymphoma cell lines and mouse models, outperforming the pan-HDAC inhibitor panobinostat or first-line\/second-line multi-drug combinations. Different from panobinostat, bulk RNA-seq analysis revealed that PM suppressed essential tumor survival factors and triggered inflammation and interferon responses. The scRNA-seq of 5TMM models further indicated that PM enhanced antitumor immunity by boosting monocyte- and T cell-mediated immune responses. In a phase I trial (NCT05526313; N\u2009=\u200929) of PM at doses up to 15\u2009mg\/m\u00b2, treatment-related Grade \u22653 adverse events predominantly comprised hematologic toxicities: thrombocytopenia (75.9%), neutropenia (55.2%), leukopenia (41.4%), and lymphopenia (31.0%), with no dose-limiting toxicities observed. PM monotherapy achieved a disease control rate of 72.7% (8\/11) and an objective response rate (ORR) of 9.1% (1\/11) in r\/r MM. Notably, r\/r lymphoma patients showed an ORR of 61.6% (11\/18), particularly reaching 63.6% (7\/11) with 6 complete responses in diffuse large B-cell lymphoma (DLBCL). Treatment responders exhibited enhanced immune activation, with elevated CD3\n                    <jats:sup>+<\/jats:sup>\n                    CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells and increased cytokine levels, such as IFN-\u03b3 and CXCL10. Overall, PM is safe and moderately effective in MM, but highly effective in lymphoma. Additionally, PM combined with pomalidomide and dexamethasone showed strong synergistic activity in r\/r MM treatment. These findings support further open-label, multicenter phase Ib\/IIa trials of PM combination therapy with immunomodulators for r\/r MM, as well as phase II monotherapy trials for r\/r DLBCL and r\/r T-cell lymphoma.\n                  <\/jats:p>","DOI":"10.1038\/s41392-025-02285-w","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T12:31:36Z","timestamp":1750854696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I\/IIb inhibitor, in relapsed\/refractory multiple myeloma and lymphoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Linyu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heying","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiguo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-163X","authenticated-orcid":false,"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-1616","authenticated-orcid":false,"given":"Weili","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-1014","authenticated-orcid":false,"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"2285_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00853-3","volume":"13","author":"N Zhang","year":"2023","unstructured":"Zhang, N. et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 13, 82 (2023).","journal-title":"Blood Cancer J."},{"key":"2285_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31430-0","volume":"13","author":"JN Vo","year":"2022","unstructured":"Vo, J. N. et al. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat. Commun. 13, 3750 (2022).","journal-title":"Nat. Commun."},{"key":"2285_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41392-023-01702-2","volume":"9","author":"Z Yu","year":"2024","unstructured":"Yu, Z. et al. Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma. Signal Transduct. Target Ther. 9, 16 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2285_CR4","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","volume":"403","author":"E Silkenstedt","year":"2024","unstructured":"Silkenstedt, E., Salles, G., Campo, E. & Dreyling, M. B-cell non-Hodgkin lymphomas. Lancet 403, 1791\u20131807 (2024).","journal-title":"Lancet"},{"key":"2285_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan, A. J. et al. Diagnosis and management of multiple myeloma: a review. JAMA 327, 464\u2013477 (2022).","journal-title":"JAMA"},{"key":"2285_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41392-023-01342-6","volume":"8","author":"A Zhao","year":"2023","unstructured":"Zhao, A. et al. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. Signal Transduct. Target Ther. 8, 71 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2285_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","volume":"277","author":"O Witt","year":"2009","unstructured":"Witt, O., Deubzer, H. E., Milde, T. & Oehme, I. HDAC family: What are the cancer relevant targets? Cancer Lett. 277, 8\u201321 (2009).","journal-title":"Cancer Lett."},{"key":"2285_CR8","first-page":"4916","volume":"62","author":"R Furumai","year":"2002","unstructured":"Furumai, R. et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62, 4916\u20134921 (2002).","journal-title":"Cancer Res."},{"key":"2285_CR9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","volume":"69","author":"ZQ Ning","year":"2012","unstructured":"Ning, Z. Q. et al. Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother. Pharm. 69, 901\u2013909 (2012).","journal-title":"Cancer Chemother. Pharm."},{"key":"2285_CR10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2022.280996","volume":"108","author":"S Rai","year":"2023","unstructured":"Rai, S. et al. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica 108, 811\u2013821 (2023).","journal-title":"Haematologica"},{"key":"2285_CR11","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.4161\/15592294.2014.983367","volume":"9","author":"S Mithraprabhu","year":"2014","unstructured":"Mithraprabhu, S. et al. Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics 9, 1511\u20131520 (2014).","journal-title":"Epigenetics"},{"key":"2285_CR12","doi-asserted-by":"crossref","unstructured":"Terpos, E., Ntanasis-Stathopoulos, I., Gavriatopoulou, M. & Dimopoulos, M. A. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 8, 7 (2018).","DOI":"10.1038\/s41408-017-0037-4"},{"key":"2285_CR13","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3324\/haematol.2017.181172","volume":"103","author":"J He","year":"2018","unstructured":"He, J. et al. Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease. Haematologica 103, 1369\u20131379 (2018).","journal-title":"Haematologica"},{"key":"2285_CR14","doi-asserted-by":"publisher","first-page":"C780","DOI":"10.1152\/ajpcell.00351.2015","volume":"310","author":"C Dou","year":"2016","unstructured":"Dou, C. et al. HDAC2 regulates FoxO1 during RANKL-induced osteoclastogenesis. Am. J. Physiol. Cell Physiol. 310, C780\u2013C787 (2016).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2285_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2217\/epi.13.73","volume":"6","author":"Z Wang","year":"2014","unstructured":"Wang, Z., Qin, G. & Zhao, T. C. HDAC4: mechanism of regulation and biological functions. Epigenomics 6, 139\u2013150 (2014).","journal-title":"Epigenomics"},{"key":"2285_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1139\/o01-116","volume":"79","author":"W Fischle","year":"2001","unstructured":"Fischle, W., Kiermer, V., Dequiedt, F. & Verdin, E. The emerging role of class II histone deacetylases. Biochem. Cell Biol. 79, 337\u2013348 (2001).","journal-title":"Biochem. Cell Biol."},{"key":"2285_CR17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.7150\/ijms.8522","volume":"11","author":"SH Lee","year":"2014","unstructured":"Lee, S. H. et al. Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance. Int. J. Med. Sci. 11, 994\u20131000 (2014).","journal-title":"Int. J. Med. Sci."},{"key":"2285_CR18","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202101742RR","volume":"36","author":"R Li","year":"2022","unstructured":"Li, R. et al. A pan-cancer analysis identifies HDAC11 as an immunological and prognostic biomarker. FASEB J. 36, e22326 (2022).","journal-title":"FASEB J."},{"key":"2285_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-022-01234-2","volume":"15","author":"M Swamydas","year":"2022","unstructured":"Swamydas, M. et al. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. J. Hematol. Oncol. 15, 17 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2285_CR20","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s13238-020-00694-x","volume":"11","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma. Protein Cell 11, 472\u2013482 (2020).","journal-title":"Protein Cell"},{"key":"2285_CR21","doi-asserted-by":"crossref","unstructured":"Yang, W. et al. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Sci. Transl. Med. 13, eaaz6804 (2021).","DOI":"10.1126\/scitranslmed.aaz6804"},{"key":"2285_CR22","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/s41375-018-0062-8","volume":"32","author":"J Bae","year":"2018","unstructured":"Bae, J. et al. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia 32, 1932\u20131947 (2018).","journal-title":"Leukemia"},{"key":"2285_CR23","doi-asserted-by":"crossref","unstructured":"Bugide, S., Gupta, R., Green, M. R. & Wajapeyee, N. EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner. Proc. Natl. Acad. Sci USA 118, e2102718118 (2021).","DOI":"10.1073\/pnas.2102718118"},{"key":"2285_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/ni.1673","volume":"10","author":"A Villagra","year":"2009","unstructured":"Villagra, A. et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat. Immunol. 10, 92\u2013100 (2009).","journal-title":"Nat. Immunol."},{"key":"2285_CR25","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1002\/ijc.29979","volume":"138","author":"H Xiao","year":"2016","unstructured":"Xiao, H. et al. HDAC5 controls the functions of Foxp3(+) T-regulatory and CD8(+) T cells. Int. J. Cancer 138, 2477\u20132486 (2016).","journal-title":"Int. J. Cancer"},{"key":"2285_CR26","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1158\/2326-6066.CIR-18-0875","volume":"7","author":"X Wang","year":"2019","unstructured":"Wang, X. et al. Histone deacetylase inhibition sensitizes PD1 blockade-resistant B-cell lymphomas. Cancer Immunol. Res. 7, 1318\u20131331 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2285_CR27","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1189\/jlb.0311119","volume":"91","author":"BR Rosborough","year":"2012","unstructured":"Rosborough, B. R. et al. Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo. J. Leukoc. Biol. 91, 701\u2013709 (2012).","journal-title":"J. Leukoc. Biol."},{"key":"2285_CR28","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/nm1652","volume":"13","author":"R Tao","year":"2007","unstructured":"Tao, R. et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13, 1299\u20131307 (2007).","journal-title":"Nat. Med."},{"key":"2285_CR29","doi-asserted-by":"publisher","first-page":"5488","DOI":"10.1021\/acs.jmedchem.6b00579","volume":"59","author":"Y Chen","year":"2016","unstructured":"Chen, Y. et al. Development of purine-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities. J. Med. Chem. 59, 5488\u20135504 (2016).","journal-title":"J. Med. Chem."},{"key":"2285_CR30","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.1158\/1078-0432.CCR-19-0516","volume":"25","author":"L Yang","year":"2019","unstructured":"Yang, L. et al. Purinostat mesylate is a uniquely potent and selective inhibitor of HDACs for the treatment of BCR-ABL-induced B-cell acute lymphoblastic leukemia. Clin. Cancer Res. 25, 7527\u20137539 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2285_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.53","volume":"3","author":"Y Hu","year":"2013","unstructured":"Hu, Y. et al. A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB\/c mice. Blood Cancer J. 3, e156 (2013).","journal-title":"Blood Cancer J."},{"key":"2285_CR32","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1200\/JCO.2016.70.6705","volume":"35","author":"S Robiou du Pont","year":"2017","unstructured":"Robiou du Pont, S. et al. Genomics of multiple myeloma. J. Clin. Oncol. 35, 963\u2013967 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2285_CR33","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/leu.2014.202","volume":"29","author":"Y Hu","year":"2015","unstructured":"Hu, Y. et al. CSNK1alpha1 mediates malignant plasma cell survival. Leukemia 29, 474\u2013482 (2015).","journal-title":"Leukemia"},{"key":"2285_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28515-1","volume":"13","author":"YLD Ng","year":"2022","unstructured":"Ng, Y. L. D. et al. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nat. Commun. 13, 1009 (2022).","journal-title":"Nat. Commun."},{"key":"2285_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-020-0113-2","volume":"5","author":"L Wang","year":"2020","unstructured":"Wang, L. et al. Advances in targeted therapy for malignant lymphoma. Signal Transduct. Target. Ther. 5, 15 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2285_CR36","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.3324\/haematol.2020.253526","volume":"106","author":"MN Zeissig","year":"2021","unstructured":"Zeissig, M. N. et al. Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo. Haematologica 106, 3176\u20133187 (2021).","journal-title":"Haematologica"},{"key":"2285_CR37","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andre","year":"2018","unstructured":"Andre, P. et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731\u20131743.e1713 (2018).","journal-title":"Cell"},{"key":"2285_CR38","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","volume":"133","author":"C Pawlyn","year":"2019","unstructured":"Pawlyn, C. & Davies, F. E. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood 133, 660\u2013675 (2019).","journal-title":"Blood"},{"key":"2285_CR39","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/nm.4229","volume":"22","author":"M Chesi","year":"2016","unstructured":"Chesi, M. et al. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat. Med. 22, 1411\u20131420 (2016).","journal-title":"Nat. Med."},{"key":"2285_CR40","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu, A. et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20, 1301\u20131309 (2014).","journal-title":"Nat. Med."},{"key":"2285_CR41","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao, H. et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct. Target. Ther. 6, 263 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2285_CR42","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2010-05-284711","volume":"117","author":"T Roger","year":"2011","unstructured":"Roger, T. et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 117, 1205\u20131217 (2011).","journal-title":"Blood"},{"key":"2285_CR43","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/leu.2010.244","volume":"25","author":"W Song","year":"2011","unstructured":"Song, W. et al. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia 25, 161\u2013168 (2011).","journal-title":"Leukemia"},{"key":"2285_CR44","doi-asserted-by":"publisher","first-page":"116538","DOI":"10.1016\/j.bone.2022.116538","volume":"164","author":"A Elson","year":"2022","unstructured":"Elson, A., Anuj, A., Barnea-Zohar, M. & Reuven, N. The origins and formation of bone-resorbing osteoclasts. Bone 164, 116538 (2022).","journal-title":"Bone"},{"key":"2285_CR45","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.3109\/10428194.2012.661175","volume":"53","author":"JL Wolf","year":"2012","unstructured":"Wolf, J. L. et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed\/refractory multiple myeloma. Leuk. Lymphoma 53, 1820\u20131823 (2012).","journal-title":"Leuk. Lymphoma"},{"key":"2285_CR46","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/10428190701817258","volume":"49","author":"P Richardson","year":"2008","unstructured":"Richardson, P. et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk. Lymphoma 49, 502\u2013507 (2008).","journal-title":"Leuk. Lymphoma"},{"key":"2285_CR47","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/cncr.25584","volume":"117","author":"R Niesvizky","year":"2011","unstructured":"Niesvizky, R. et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 117, 336\u2013342 (2011).","journal-title":"Cancer"},{"key":"2285_CR48","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/s41401-021-00728-y","volume":"43","author":"YB Zhou","year":"2022","unstructured":"Zhou, Y. B. et al. Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma. Acta Pharm. Sin. 43, 1091\u20131099 (2022).","journal-title":"Acta Pharm. Sin."},{"key":"2285_CR49","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/annonc\/mdn031","volume":"19","author":"M Crump","year":"2008","unstructured":"Crump, M. et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann. Oncol. 19, 964\u2013969 (2008).","journal-title":"Ann. Oncol."},{"key":"2285_CR50","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.3109\/10428194.2015.1135431","volume":"57","author":"SD Puvvada","year":"2016","unstructured":"Puvvada, S. D. et al. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk. Lymphoma 57, 2359\u20132369 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"2285_CR51","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson, N. A. et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 30, 3452\u20133459 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2285_CR52","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/leu.2014.238","volume":"29","author":"EM Ocio","year":"2015","unstructured":"Ocio, E. M. et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia 29, 705\u2013714 (2015).","journal-title":"Leukemia"},{"key":"2285_CR53","first-page":"483","volume":"21","author":"Q Qiu","year":"2023","unstructured":"Qiu, Q. et al. HDAC I\/IIb selective inhibitor purinostat mesylate combined with GLS1 inhibition effectively eliminates CML stem cells. Bioact. Mater. 21, 483\u2013498 (2023).","journal-title":"Bioact. Mater."},{"key":"2285_CR54","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo, M. et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998\u20131013 (2014).","journal-title":"Cancer Discov."},{"key":"2285_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04556-8","volume":"13","author":"F Wang","year":"2022","unstructured":"Wang, F. et al. ALCAM regulates multiple myeloma chemoresistant side population. Cell Death Dis. 13, 136 (2022).","journal-title":"Cell Death Dis."},{"key":"2285_CR56","first-page":"800","volume":"56","author":"JR Liu","year":"2017","unstructured":"Liu, J. R. & Li, J. The guidelines for the diagnosis and management of multiple myeloma in China (2017 revision): interpretation of response criteria. Zhonghua Nei Ke Za Zhi 56, 800\u2013803 (2017).","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"2285_CR57","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"2285_CR58","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","volume":"28","author":"A Younes","year":"2017","unstructured":"Younes, A. et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann. Oncol. 28, 1436\u20131447 (2017).","journal-title":"Ann. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02285-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02285-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02285-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T14:01:54Z","timestamp":1750860114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02285-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2285"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02285-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"201"}}